


Oncogramme®

Towards personalised medicine for all cancer patients

Chances of response to first-line treatment for metastatic colorectal cancer



Without
Oncogramme®



With
Oncogramme®



What is the Oncogramme® ?

The **Oncogramme® predicts the anti-cancer activity of existing drugs** by testing them directly on a patient's operated tumour. Their efficacy is evaluated on a sample of this tumour *ex vivo*, using an approach comparable to that of the antibiogram.

How can treatment be personalised?

Every cancer patient requires special attention, ideally involving individualised treatment. The majority of patients today need chemotherapy to fight cancer effectively, but no test or biomarker can predict the effectiveness of treatments or combinations of treatments. Targeted therapies are a first line of defence against the disease, but not all people are eligible for them.

Based on a similar model to the antibiogram, **our French laboratory has developed and marketed its own functional test**. Functional tests are an **important tool to help in the choice of chemotherapy**. A recent review showed that functional tests had **an efficiency of 80%** (Bounaix Morand du Puch et al., *Theranostics*. 2021 Sep 21;11(19):9538-9556).

Since 2016, patients with **stage IV colorectal cancer** can benefit from the Oncogramme®: a unique solution to personalise chemotherapy.

The Oncogramme® will soon be optimised for other cancers such as **breast cancer and ovarian cancer**, to improve treatment by tailoring it to each patient.

01



SURGERY
Biopsy or
resection



ANALYSIS
of the cellular
response

02

Oncogramme®



RESULTS
Sensitivity of
tumour cells to
treatment


03



**CUSTOMIZED
TREATMENT**

04

Metastatic colorectal cancer is the first indication for the CE marked Oncogramme® DM-DIV.



FOLFIRINOX: oxaliplatin, irinotecan, 5-fluorouracil + folinic acid
FOLFIRI: irinotecan, 5-fluorouracil + folinic acid
FOLFOX: oxaliplatin, 5-Fluorouracil + Folinic acid

Oncomedics' results with the Oncogram® in metastatic colorectal cancer suggest an increased chance of response to first-line treatments: 84% (Bounaix Morand du Puch et al. J Transl Med. 2016 Jan 12;14:10) compared to 21% (5-FU alone) to 48% (FOLFOX) at best in the literature (Pfeiffer et al. Onco Targets Ther. 2009; 2:17-27) for the main consensus chemotherapy treatments.

